GILD logo

Gilead Sciences, Inc.

GILD
Healthcare|Drug Manufacturers - General|US
$166.89
-0.68 (-0.41%)
DCF Value
$137.19
Cash / Share
$5.18

Financials

Financial Snapshot

Market Cap
$207.00B
Enterprise Value
$226.79B
Revenue (TTM)
$30.99B
Net Income (TTM)
-$3.86B
Cash & Investments
$6.44B
Net Cash
-$19.79B
Free Cash Flow (TTM)
$14.04B
Operating CF (TTM)
$14.48B
Debt/Equity
2.01

Cash Runway & Burn Rate

Company is cash-flow positive.

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Investments
$11.89B$25.51B$30.09B$24.35B$7.41B$6.52B$6.38B$7.26B$11.57B$9.61B$6.44B
Operating Cash Flow
$17.05B$11.90B$8.40B$9.14B$8.17B$11.38B$9.07B$8.01B$10.83B$10.02B$14.48B
Free Cash Flow
$16.30B$11.31B$7.48B$8.32B$7.52B$10.80B$8.34B$7.42B$10.30B$9.46B$14.04B
Capital Expenditure
-$748.0M-$590.0M-$924.0M-$825.0M-$650.0M-$579.0M-$728.0M-$585.0M-$523.0M-$563.0M-$442.0M
Financing Cash Flow
-$9.72B$3.39B-$12.32B-$7.63B$770.0M-$8.88B-$6.47B-$5.13B-$3.43B-$7.75B-$4.69B

R&D Spending

R&D (TTM)
$6.33B
R&D Intensity
20.4%
R&D Growth vs Prior
+9.1%
MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$30.39B$26.11B$22.13B$22.45B$24.69B$27.30B$27.28B$27.12B$28.75B$29.44B$30.99B
R&D Expense
$5.10B$3.73B$3.92B$4.05B$5.04B$4.60B$4.98B$5.72B$5.91B$5.80B$6.33B
R&D % of Revenue
16.8%14.3%17.7%18.1%20.4%16.9%18.2%21.1%20.5%19.7%20.4%
SG&A
$3.40B$3.88B$4.06B$4.38B$5.11B$5.25B$5.67B$6.09B$6.09B$5.71B$6.74B

Income Statement

MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$30.39B$26.11B$22.13B$22.45B$24.69B$27.30B$27.28B$27.12B$28.75B$29.44B$30.99B
Cost of Revenue
$4.26B$4.37B$4.85B$4.67B$4.57B$6.60B$5.66B$6.50B$6.25B$6.23B$6.22B
Gross Profit
$26.13B$21.74B$17.27B$17.77B$20.12B$20.70B$21.62B$20.62B$22.50B$23.21B$24.77B
R&D
$5.10B$3.73B$3.92B$4.05B$5.04B$4.60B$4.98B$5.72B$5.91B$5.80B$6.33B
SG&A
$3.40B$3.88B$4.06B$4.38B$5.11B$5.25B$5.67B$6.09B$6.09B$5.71B$6.74B
Operating Income
$17.63B$14.12B$8.20B$4.29B$4.07B$9.92B$7.33B$7.61B$1.66B$11.70B-$1.36B
Interest Expense
$964.0M$1.12B$1.08B$995.0M$984.0M$1.00B$935.0M$944.0M$977.0M$1.02B$1.01B
Pretax Income
$17.10B$13.53B$7.80B$5.16B$1.67B$8.28B$5.81B$6.86B$690.0M$9.80B-$2.53B
Net Income
$13.50B$4.63B$5.46B$5.39B$123.0M$6.22B$4.59B$5.67B$480.0M$8.51B-$3.86B
EPS (Diluted)
9.943.514.174.220.104.933.644.500.386.78-3.16
EBITDA
$19.22B$15.93B$10.30B$7.56B$4.13B$11.33B$8.85B$10.50B$4.43B$13.58B$823.0M
Shares Out. (M)
1358.001319.001308.001277.001263.001262.001262.001258.001255.001255.001251.00

Balance Sheet

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Equivalents
$8.23B$7.59B$17.94B$11.63B$6.00B$5.34B$5.41B$6.08B$9.99B$7.56B$6.44B
Short-Term Investments
$3.67B$17.92B$12.15B$12.72B$1.41B$1.18B$973.0M$1.18B$1.58B$2.05B$0.00
Total Current Assets
$19.59B$31.82B$35.84B$30.30B$16.00B$14.77B$14.44B$16.09B$19.17B$18.34B$16.55B
Total Assets
$56.98B$70.28B$63.67B$61.63B$68.41B$67.95B$63.17B$62.13B$58.99B$59.02B$51.41B
Total Current Liabilities
$9.22B$11.63B$10.61B$9.76B$11.40B$11.61B$11.24B$11.28B$12.00B$11.81B$12.00B
Long-Term Debt
$26.35B$30.80B$24.57B$22.09B$28.64B$25.18B$22.96B$23.19B$24.90B$22.13B$23.82B
Total Liabilities
$37.61B$49.78B$42.14B$38.98B$50.19B$46.89B$41.96B$39.38B$39.75B$36.41B$38.45B
Stockholders' Equity
$18.89B$20.44B$21.39B$22.52B$18.20B$21.07B$21.24B$22.83B$19.33B$22.70B$13.04B
Retained Earnings
$18.15B$19.01B$19.02B$19.39B$14.38B$16.32B$15.69B$16.30B$11.50B$13.73B$3.11B

Cash Flow Statement

MetricTrend2016201720182019202020212022202320242025TTM
Operating Cash Flow
$17.05B$11.90B$8.40B$9.14B$8.17B$11.38B$9.07B$8.01B$10.83B$10.02B$14.48B
Capital Expenditure
-$748.0M-$590.0M-$924.0M-$825.0M-$650.0M-$579.0M-$728.0M-$585.0M-$523.0M-$563.0M-$442.0M
Free Cash Flow
$16.30B$11.31B$7.48B$8.32B$7.52B$10.80B$8.34B$7.42B$10.30B$9.46B$14.04B
Investing Cash Flow
-$11.98B-$16.07B$14.36B-$7.82B-$14.62B-$3.13B-$2.47B-$2.27B-$3.45B-$4.79B-$10.65B
Financing Cash Flow
-$9.72B$3.39B-$12.32B-$7.63B$770.0M-$8.88B-$6.47B-$5.13B-$3.43B-$7.75B-$4.69B
Issuance of Stock
$208.0M$234.0M$289.0M$209.0M$256.0M$169.0M$309.0M$232.0M$422.0M$408.0M$294.0M
Repurchase of Stock
-$11.00B-$954.0M-$2.90B-$1.75B-$1.58B-$546.0M-$1.40B-$1.00B-$1.15B-$1.92B-$1.37B
Net Debt Issuance
$4.27B$7.17B-$6.25B-$2.75B$5.68B-$4.75B-$1.50B-$270.0M$1.49B-$1.79B$1.27B
Stock Based Comp.
$380.0M$638.0M$845.0M$636.0M$643.0M$635.0M$644.0M$766.0M$835.0M$894.0M$464.0M
Net Change in Cash
-$4.62B-$641.0M$10.35B-$6.31B-$5.63B-$659.0M$74.0M$673.0M$3.91B-$2.43B-$890.0M

Dilution Tracker

Shares Outstanding
1240M
5-Year Share Growth
-0.6%
Stock Issuance (TTM)
$294.0M
MetricTrend2016201720182019202020212022202320242025TTM
Shares Out. (M)
1358.001319.001308.001277.001263.001262.001262.001258.001255.001255.001251.00
Change vs Prior %
—-2.9%-0.8%-2.4%-1.1%-0.1%0.0%-0.3%-0.2%0.0%-0.3%
Stock Issuance
$208.0M$234.0M$289.0M$209.0M$256.0M$169.0M$309.0M$232.0M$422.0M$408.0M$294.0M
Stock Repurchase
-$11.00B-$954.0M-$2.90B-$1.75B-$1.58B-$546.0M-$1.40B-$1.00B-$1.15B-$1.92B-$1.37B
Stock Based Comp.
$380.0M$638.0M$845.0M$636.0M$643.0M$635.0M$644.0M$766.0M$835.0M$894.0M$464.0M

Margins & Profitability

MetricTrend2016201720182019202020212022202320242025TTM
Gross Margin %
86.0%83.3%78.1%79.2%81.5%75.8%79.3%76.0%78.3%78.8%79.9%
Operating Margin %
58.0%54.1%37.1%19.1%16.5%36.3%26.9%28.0%5.8%39.7%-4.4%
Net Margin %
44.4%17.7%24.7%24.0%0.5%22.8%16.8%20.9%1.7%28.9%-12.5%
EBITDA Margin %
63.2%61.0%46.6%33.7%16.7%41.5%32.4%38.7%15.4%46.1%2.7%
FCF Margin %
53.6%43.3%33.8%37.1%30.5%39.6%30.6%27.4%35.8%32.1%45.3%
ROE %
71.5%22.6%25.5%23.9%0.7%29.5%21.6%24.8%2.5%37.5%-21.7%
ROA %
23.7%6.6%8.6%8.7%0.2%9.2%7.3%9.1%0.8%14.4%-7.5%
ROIC %
29.1%7.9%10.3%7.9%0.4%12.8%10.6%11.8%2.4%20.3%-3.2%
R&D / Revenue %
16.8%14.3%17.7%18.1%20.4%16.9%18.2%21.1%20.5%19.7%20.4%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
-6.9%-14.1%-15.2%1.5%10.0%10.6%-0.1%-0.6%6.0%2.4%
Gross Profit
-8.7%-16.8%-20.5%2.9%13.2%2.9%4.4%-4.7%9.1%3.1%
Operating Income
-20.5%-19.9%-41.9%-47.7%-5.0%143.6%-26.1%3.8%-78.1%604.0%
Net Income
-25.4%-65.7%17.9%-1.3%-97.7%4961.0%-26.2%23.4%-91.5%1672.9%
EPS (Diluted)
-16.5%-64.7%18.8%1.2%-97.7%4961.6%-26.2%23.6%-91.6%1684.2%
Operating Cash Flow
-19.8%-30.2%-29.4%8.9%-10.7%39.4%-20.3%-11.8%35.2%-7.5%
Free Cash Flow
-20.5%-30.6%-33.9%11.3%-9.6%43.7%-22.8%-11.1%38.9%-8.2%
R&D Expense
69.1%-26.8%5.0%3.4%24.3%-8.7%8.2%14.9%3.3%-1.8%
SG&A Expense
-0.8%14.1%4.6%8.0%16.7%2.6%8.1%7.4%0.0%-6.3%
Total Assets
10.2%23.4%-9.4%-3.2%11.0%-0.7%-7.0%-1.7%-5.0%0.0%
Book Value / Share
10.8%8.5%5.8%7.5%-18.7%15.7%0.8%7.9%-15.3%17.8%
Debt
19.5%27.3%-18.5%-10.0%27.7%-15.0%-5.5%-1.0%6.9%-6.6%
Diluted Shares
-10.7%-2.9%-0.8%-2.4%-1.1%-0.1%0.0%-0.3%-0.2%0.0%

Valuation

P/E (TTM)At Loss
10Y Low / Med / High7.10 / 17.94 / 595.10
P/S6.68
10Y Low / Med / High2.97 / 3.68 / 5.19
P/B15.90
10Y Low / Med / High3.66 / 4.58 / 6.73
EV/EBITDA275.57
10Y Low / Med / High5.93 / 12.52 / 29.75
EV/Revenue7.32
10Y Low / Med / High3.75 / 4.43 / 5.78
P/FCF14.75
10Y Low / Med / High5.88 / 10.86 / 16.15

Intrinsic Value Models (per share)

DCF Value
$137.19
Cash / Share
$5.18
MetricTrend2016201720182019202020212022202320242025TTM
P/E Ratio
7.1020.2414.8915.33595.1014.6423.4617.84243.0817.94-53.84
P/S Ratio
3.163.593.673.682.973.343.953.734.015.196.68
P/B Ratio
5.084.583.803.664.024.335.074.435.966.7315.90
EV/EBITDA
5.937.518.7912.6323.879.9414.4111.4329.7512.52275.57
EV/Revenue
3.754.584.094.254.004.124.684.434.595.787.32

Analyst Estimates & Quality

Altman Z-Score
3.90
Safe
Piotroski F-Score
5
Moderate

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$31.27B$33.49B$34.78B
Net Income-$1.25B$12.67B$13.45B
EPS$-0.85$10.10$10.78
# Analysts (EPS)141610

Dividends

Dividend/Share (TTM)
$3.25
Dividend Yield
1.95%
Frequency
Quarterly
Next Payment
Dec 30, 2026

Recent Payments

Ex-DatePay DateAmountFrequency
Dec 15, 2026Dec 30, 2026$0.82Quarterly
Sep 15, 2026Sep 29, 2026$0.82Quarterly
Jun 15, 2026Jun 29, 2026$0.82Quarterly
Mar 13, 2026Mar 30, 2026$0.82Quarterly
Dec 15, 2025Dec 30, 2025$0.79Quarterly
Sep 15, 2025Sep 29, 2025$0.79Quarterly
Jun 13, 2025Jun 27, 2025$0.79Quarterly
Mar 14, 2025Mar 28, 2025$0.79Quarterly
Dec 13, 2024Dec 30, 2024$0.77Quarterly
Sep 13, 2024Sep 27, 2024$0.77Quarterly
Jun 14, 2024Jun 27, 2024$0.77Quarterly
Mar 14, 2024Mar 28, 2024$0.77Quarterly
Dec 14, 2023Dec 28, 2023$0.75Quarterly
Sep 14, 2023Sep 28, 2023$0.75Quarterly
Jun 14, 2023Jun 29, 2023$0.75Quarterly
Mar 14, 2023Mar 30, 2023$0.75Quarterly
Dec 14, 2022Dec 29, 2022$0.73Quarterly
Sep 14, 2022Sep 29, 2022$0.73Quarterly
Jun 14, 2022Jun 29, 2022$0.73Quarterly
Mar 14, 2022Mar 30, 2022$0.73Quarterly

Revenue Segments

By Product

Segment202020212022202320242025
Cell Therapy Products, Total Cell Therapy Product Sales$607.0M$1.05B$1.76B$2.24B$2.38B—
Other Products, Total Other product sales$1.89B$1.03B$946.0M$859.0M$889.0M—
Products, Other HIV$17.00B$16.36B$17.25B$18.23B$19.61B—
Hepatitis B Virus / Hepatitis Delta Virus Product—$969.0M$988.0M$1.02B——
Trodelvy—$380.0M$680.0M$1.06B$1.31B$1.40B
Veklury—$5.57B$3.90B$2.18B$1.80B$911.0M
Biktarvy—————$14.33B
Descovy—————$2.76B
Genvoya—————$1.50B
Odefsey—————$1.17B
Symtuza - Revenue share—————$495.0M
Other HIV—————$500.0M
Tecartus—————$344.0M
Yescarta—————$1.50B
Sofosbuvir/Velpatasvir—————$1.27B
Vemlidy—————$1.07B
Other Liver Disease—————$874.0M
AmBisome—————$509.0M
Other—————$290.0M
Royalty, contract and other revenues—————$527.0M

By Geography

Segment202020212022202320242025
Europe$4.13B$4.87B$4.47B$4.31B$4.63B$5.06B
Other International$2.34B$3.16B$3.93B$3.37B$3.53B$3.50B
UNITED STATES$18.22B$19.27B$18.88B$19.44B$20.59B$20.88B